Reversible myocardial dysfunction in sepsis and ischemia*

Kan, Hong; Failinger, Conard; Fang, Qiujuan; Finkel, Mitchell S.

doi:10.1097/01.ccm.0000190906.89407.36

Cited by 6 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The structure gradually changed, including the vasculature, and the myofilaments gradually caused damage to the myocardial fibre structure. 15,17 During severe sepsis, cardiac output is normal or increased, peripheral vascular resistance is decreased, and coronary artery blood flow is increased. Additional abnormalities may include increased lactic acid and free fatty acids, abnormal glucose utilisation, hypoxic coronary sinuses, and caecal ligation- and puncture-induced sepsis as seen in mouse models of high-power sepsis (i.e., high kinetic metabolism, increased cardiac output, decreased peripheral vascular resistance, and increased heart rate in the early stage of sepsis).…”

Section: Myocardial Ischaemiamentioning

confidence: 99%

Levosimendan as a new force in the treatment of sepsis-induced cardiomyopathy: mechanism and clinical application

et al. 2019

View full text Add to dashboard Cite

The heart is one of the organs most vulnerable to sepsis. This review describes the general characteristics of sepsis-induced cardiomyopathy and the main pathogenesis of myocardial dysfunction in sepsis. Levosimendan is a novel drug for treatment of sepsis-induced myocardial dysfunction. This review also elaborates on the pathogenesis of levosimendan, including the mechanisms of its anti-inflammatory effects, improvement of myocardial ischaemia, increased synthesis of nitric oxide, vascular endothelial cell protection, increased myocardial contractility, improved diastolic function, and inhibition of hypoxia-inducible factor-1α expression. Many clinical studies have proven that levosimendan effectively prevents myocardial dysfunction in sepsis. In addition to the widespread use of levosimendan in patients with heart failure, the role of levosimendan in the treatment of patients with sepsis-induced cardiomyopathy will be increasingly studied and applied in the future.

show abstract

Section: Myocardial Ischaemiamentioning

confidence: 99%

Levosimendan as a new force in the treatment of sepsis-induced cardiomyopathy: mechanism and clinical application

et al. 2019

View full text Add to dashboard Cite

show abstract

Focused Cardiac Ultrasonography in the Emergent Patient

2014

View full text Add to dashboard Cite

Emergency Echocardiography

Weekes

Quirke²

2011

Emergency Medicine Clinics of North America

View full text Add to dashboard Cite

Emergency echocardiography refers to the use of cardiac ultrasound to address critical and time-sensitive clinical questions during the initial evaluation and treatment of the critically ill patient presenting to the emergency department. The information obtained can be pivotal to a physician's clinical decision making and can guide further diagnostic or therapeutic interventions. This article provides an evidence-based discussion of the common uses of emergency transthoracic echocardiography, as well as its benefits and limitations in the current practice of emergency medicine.

show abstract

Reversible myocardial dysfunction in sepsis and ischemia*

Cited by 6 publications

References 40 publications

Levosimendan as a new force in the treatment of sepsis-induced cardiomyopathy: mechanism and clinical application

Levosimendan as a new force in the treatment of sepsis-induced cardiomyopathy: mechanism and clinical application

Focused Cardiac Ultrasonography in the Emergent Patient

Emergency Echocardiography

Contact Info

Product

Resources

About